Skip to main navigation Skip to search Skip to main content

Inferring structural variant cancer cell fraction

  • PCAWG Evolution and Heterogeneity Working Group
  • , PCAWG Consortium
  • Royal Melbourne Hospital
  • Epworth HealthCare
  • University of Melbourne
  • Walter and Eliza Hall Institute of Medical Research
  • Murdoch Children's Research Institute
  • University of Glasgow
  • Cancer Research UK Cambridge Institute
  • University of Melbourne
  • CSIRO
  • Australian National University
  • Wellcome Sanger Institute
  • Oregon Health and Science University
  • Broad Institute
  • Dana-Farber Cancer Institute
  • Harvard University
  • Ontario Institute for Cancer Research
  • University of Toronto
  • University of California at Los Angeles
  • Peter Maccallum Cancer Centre
  • University of Cambridge
  • Cambridge University Hospitals NHS Foundation Trust
  • University of Texas MD Anderson Cancer Center
  • University of Cologne
  • KU Leuven
  • The Francis Crick Institute
  • University of Oxford
  • Simon Fraser University
  • Vancouver Prostate Centre
  • German Cancer Research Center
  • Heidelberg University 
  • Berlin Institute of Health (BIH) and Charité - Universitätsmedizin Berlin
  • European Molecular Biology Laboratory
  • Massachusetts General Hospital
  • New York Genome Center
  • Cornell University
  • University of Ljubljana
  • NorthShore University HealthSystem
  • The University of Chicago
  • University of California at Santa Cruz
  • Vector Institute
  • University of Helsinki
  • Carleton College
  • Princeton University
  • Indiana University Bloomington

Research output: Contribution to journalArticlepeer-review

Abstract

We present SVclone, a computational method for inferring the cancer cell fraction of structural variant (SV) breakpoints from whole-genome sequencing data. SVclone accurately determines the variant allele frequencies of both SV breakends, then simultaneously estimates the cancer cell fraction and SV copy number. We assess performance using in silico mixtures of real samples, at known proportions, created from two clonal metastases from the same patient. We find that SVclone’s performance is comparable to single-nucleotide variant-based methods, despite having an order of magnitude fewer data points. As part of the Pan-Cancer Analysis of Whole Genomes (PCAWG) consortium, which aggregated whole-genome sequencing data from 2658 cancers across 38 tumour types, we use SVclone to reveal a subset of liver, ovarian and pancreatic cancers with subclonally enriched copy-number neutral rearrangements that show decreased overall survival. SVclone enables improved characterisation of SV intra-tumour heterogeneity.

Original languageEnglish
Article number730
JournalNature Communications
Volume11
Issue number1
DOIs
StatePublished - 1 Dec 2020

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Fingerprint

Dive into the research topics of 'Inferring structural variant cancer cell fraction'. Together they form a unique fingerprint.

Cite this